Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies for genetic diseases, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The data demonstrate that the company's next-generation suppressor tRNAs (sup-tRNAs) achieve complete restoration of full-length dystrophin protein and wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, Tevard showed durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
The findings underscore the potential of Tevard's sup-tRNA platform to address a broad range of genetic diseases caused by premature termination codons. According to the company, its compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. This versatility is critical for treating conditions like DMD and DCM-TTNtv, where current therapies often only address symptoms or slow disease progression.
Duchenne muscular dystrophy affects approximately 1 in 3,500 male births worldwide, leading to progressive muscle degeneration and premature death. Nonsense mutations account for about 13% of DMD cases. Tevard's sup-tRNAs are designed to read through premature stop codons and restore native, full-length protein expression. The presented data showing ~100% dystrophin restoration in mouse models suggest a significant therapeutic advantage over existing treatments, which typically result in partial or truncated protein production.
Similarly, dilated cardiomyopathy is a leading cause of heart failure, and truncating variants in the TTN gene are the most common genetic cause. Tevard's novel sup-tRNAs provided durable rescue of full-length titin in a mouse model and functional improvement in human cardiomyocyte models. This could offer a transformative approach for patients with DCM-TTNtv, for whom no disease-modifying therapies currently exist.
The suppressor tRNA platform's ability to restore endogenous protein expression in a cell-specific, durable manner highlights its potential across multiple indications. Tevard is advancing programs in muscular dystrophies, heart disease, and neurological disorders. The company's next-generation sup-tRNAs represent a significant evolution in tRNA-based therapy, with improved potency and delivery characteristics.
For more information about Tevard Biosciences and its pipeline, visit www.tevard.com.
